Send to

Choose Destination
See comment in PubMed Commons below
Version 3. PLoS Curr. 2012 Feb 15 [revised 2012 Mar 26];4:RRN1304.

Current Pharmacological Management in Juvenile Huntington's Disease.

Author information

  • 1Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield UK S10 2TH; Neurogenetics and Rare Diseases Centre, IRCCS Neuromed, Pozzilli (IS), Italy.; University of Cambridge; Department of Clinical Neurophysiology, Institute of Psychiatry and Naurology, Warsaw, Poland and Dept. of Neurology, University of Ulm, Ulm, Germany.



The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management.


To survey the current use of pharmacological treatments for JHD.


Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study.


The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications.


The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk